<?xml version='1.0' encoding='utf-8'?>
<document id="29788155"><sentence text="Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors."><entity charOffset="80-91" id="DDI-PubMed.29788155.s1.e0" text="gemcitabine" /></sentence><sentence text="Checkpoint kinase 1 (Chk1) inhibition following chemotherapy-elicited DNA damage overrides cell cycle arrest and induces mitotic catastrophe and cell death" /><sentence text=" GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor that results in tumor shrinkage and growth delay in xenograft models" /><sentence text=" We evaluated the safety, tolerability, and pharmacokinetic properties of GDC-0575 alone and in combination with gemcitabine"><entity charOffset="113-124" id="DDI-PubMed.29788155.s4.e0" text="gemcitabine" /></sentence><sentence text=" Antitumor activity and Chk1 pathway modulation were assessed" /><sentence text="" /><sentence text="In this phase I open-label study, in the dose escalation stage, patients were enrolled in a GDC-0575 monotherapy Arm (1) or GDC-0575 combination with gemcitabine Arm (2) to determine the maximum tolerated dose"><entity charOffset="150-161" id="DDI-PubMed.29788155.s7.e0" text="gemcitabine" /></sentence><sentence text=" Patients in arm 2 received either i" /><sentence text="v" /><sentence text=" gemcitabine 1000 mg/m2 (arm 2a) or 500 mg/m2 (arm 2b), followed by GDC-0575 (45 or 80 mg, respectively, as RP2D)"><entity charOffset="1-12" id="DDI-PubMed.29788155.s10.e0" text="gemcitabine" /></sentence><sentence text=" Stage II enrolled disease-specific cohorts" /><sentence text="" /><sentence text="Of 102 patients treated, 70% were female, the median age was 59 years (range 27-85), and 47% were Eastern Cooperative Oncology Group PS 0" /><sentence text=" The most common tumor type was breast (37%)" /><sentence text=" The most frequent adverse events (all grades) related to GDC-0575 and/or gemcitabine were neutropenia (68%), anemia (48%), nausea (43%), fatigue (42%), and thrombocytopenia (35%)"><entity charOffset="74-85" id="DDI-PubMed.29788155.s15.e0" text="gemcitabine" /></sentence><sentence text=" Maximum concentrations of GDC-0575 were achieved within 2 hours of dosing, and half-life was ∼23 hours" /><sentence text=" No pharmacokinetic drug-drug interaction was observed between GDC-0575 and gemcitabine"><entity charOffset="76-87" id="DDI-PubMed.29788155.s17.e0" text="gemcitabine" /></sentence><sentence text=" Among patients treated with GDC-0575 and gemcitabine, there were four confirmed partial responses, three occurring in patients with tumors harboring TP53 mutation"><entity charOffset="29-37" id="DDI-PubMed.29788155.s18.e0" text="GDC-0575" /><entity charOffset="42-53" id="DDI-PubMed.29788155.s18.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.29788155.s18.e0" e2="DDI-PubMed.29788155.s18.e0" /><pair ddi="false" e1="DDI-PubMed.29788155.s18.e0" e2="DDI-PubMed.29788155.s18.e1" /></sentence><sentence text=" Pharmacodynamic data were consistent with GDC-0575 inhibition of gemcitabine-induced expression of pCDK1/2"><entity charOffset="66-77" id="DDI-PubMed.29788155.s19.e0" text="gemcitabine" /></sentence><sentence text="" /><sentence text="GDC-0575 can be safely administered as a monotherapy and in combination with gemcitabine; however, overall tolerability with gemcitabine was modest"><entity charOffset="77-88" id="DDI-PubMed.29788155.s21.e0" text="gemcitabine" /><entity charOffset="125-136" id="DDI-PubMed.29788155.s21.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.29788155.s21.e0" e2="DDI-PubMed.29788155.s21.e0" /><pair ddi="false" e1="DDI-PubMed.29788155.s21.e0" e2="DDI-PubMed.29788155.s21.e1" /></sentence><sentence text=" Hematological toxicities were frequent but manageable" /><sentence text=" Preliminary antitumor activity was observed but limited to a small number of patients with a variety of refractory solid tumors treated with GDC-0575 and gemcitabine"><entity charOffset="142-150" id="DDI-PubMed.29788155.s23.e0" text="GDC-0575" /><entity charOffset="155-166" id="DDI-PubMed.29788155.s23.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.29788155.s23.e0" e2="DDI-PubMed.29788155.s23.e0" /><pair ddi="false" e1="DDI-PubMed.29788155.s23.e0" e2="DDI-PubMed.29788155.s23.e1" /></sentence><sentence text="" /><sentence text="NCT01564251" /><sentence text="" /></document>